UNITED THERAPEUTICS Corp (UTHR) KPIs and segments
Close on Nov 18, 2026Market cap $24.76BP/E 20.7Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của United Therapeutics · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của United Therapeutics: 43 chỉ số vận hành, trong đó có Top Specialty Distributor #1, Top Specialty Distributor #2 và Gross-to-Net Accrued Deductions Liability, lấy từ 77 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tyvaso DPI($M)2 | 327 | 330 | 339 | 336 | 315 | 303 | 273 | 275 | 258 | 228 | 214 | ||
United States($M) | 327 | 330 | 338 | 336 | 315 | 303 | 273 | 275 | 258 | 228 | 214 | ||
ROW($M) | 0 | 0 | 0.30 | 0 | 0.40 | 0 | 0.40 | 0 | 0 | 0 | 0 | ||
Remodulin($M)2 | 126 | 127 | 128 | 126 | 135 | 138 | 135 | 128 | 147 | 128 | 115 | ||
United States($M) | 99.4 | 109 | 104 | 111 | 114 | 120 | 118 | 115 | 123 | 108 | 106 | ||
ROW($M) | 26.9 | 17.8 | 23.7 | 15.2 | 21 | 18 | 16.5 | 12.9 | 24.8 | 19.7 | 8.80 | ||
Nebulized Tyvaso($M)2 | 126 | 127 | 126 | 142 | 154 | 164 | 143 | 159 | 140 | 145 | 137 | ||
United States($M) | 110 | 113 | 119 | 134 | 141 | 139 | 136 | 145 | 130 | 134 | 124 | ||
ROW($M) | 16.3 | 14.6 | 6.80 | 7.90 | 13.9 | 25.2 | 6.30 | 14 | 9.70 | 11.3 | 13.2 | ||
Orenitram($M)2 | 126 | 136 | 121 | 131 | 124 | 121 | 108 | 113 | 107 | 106 | 84.1 | ||
United States($M) | 126 | 136 | 121 | 131 | 124 | 121 | 108 | 113 | 107 | 106 | 84.1 | ||
ROW($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Unituxin($M)2 | 65.2 | 53.6 | 62.3 | 47.9 | 58.4 | 58.2 | 67.5 | 61.1 | 51.7 | 58.4 | 54.2 | ||
United States($M) | 59 | 49 | 55.9 | 46.5 | 55.4 | 56.9 | 61.8 | 57.6 | 46.8 | 53.4 | 48.7 | ||
ROW($M) | 6.20 | 4.60 | 6.40 | 1.40 | 3 | 1.30 | 5.70 | 3.50 | 4.90 | 5 | 5.50 | ||
Other($M)2 | 6.80 | 5.30 | 6.60 | 6.90 | 5.50 | 5 | 5.50 | 5.50 | 4.90 | 6.20 | 3.90 | ||
United States($M) | 6.50 | 5 | 6.40 | 6.70 | 5 | 4.70 | 4.20 | 4.30 | 4.60 | 6 | 2.60 | ||
ROW($M) | 0.30 | 0.30 | 0.20 | 0.20 | 0.50 | 0.30 | 1.30 | 1.20 | 0.30 | 0.20 | 1.30 | ||
Adcirca($M)2 | 6.70 | 2.90 | 7.80 | 9.70 | 6.50 | 6 | 4.70 | 7 | 5.70 | 6.40 | 6.80 | ||
United States($M) | 6.70 | 2.90 | 7.80 | 9.70 | 6.50 | 6 | 4.70 | 7 | 5.70 | 6.40 | 6.80 | ||
ROW($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
United States($M) | 734 | 744 | 753 | 775 | 760 | 750 | 706 | 717 | 675 | 642 | 586 | ||
ROW($M) | 49.7 | 37.3 | 37.4 | 24.7 | 38.8 | 44.8 | 30.2 | 31.6 | 39.7 | 36.2 | 28.8 | ||
Tyvaso DPI($M) | 276 | 247 | 280 | 281 | 267 | 254 | 235 | 236 | 221 | 194 | 183 | ||
Orenitram($M) | 120 | 128 | 114 | 124 | 117 | 112 | 102 | 106 | 101 | 97 | 78.9 | ||
Nebulized Tyvaso($M) | 117 | 119 | 119 | 135 | 149 | 155 | 135 | 150 | 132 | 136 | 128 | ||
Remodulin($M) | 109 | 111 | 120 | 113 | 120 | 124 | 121 | 115 | 135 | 120 | 103 | ||
Unituxin($M) | 63.2 | 48.6 | 56.4 | 44.3 | 55.6 | 53 | 65.3 | 56.3 | 47.9 | 54.8 | 49.2 | ||
Adcirca($M) | 3.70 | 1.90 | 4.40 | 5.30 | 3.80 | 3.40 | 2.90 | 3.90 | 3.10 | 3.80 | 4.10 | ||
Other($M) | -4.20 | -6.80 | -7.40 | -4.10 | -1.50 | -1 | -1.50 | -0.30 | -1.80 | -1.20 | -2.20 | ||
Top Specialty Distributor #1 — Share of Total Revenues(%) | 50.0% | 48.0% | 52.0% | 52.0% | 51.0% | 52.0% | 52.0% | 51.0% | 51.0% | ||||
Top Specialty Distributor #2 — Share of Total Revenues(%) | 40.0% | 37.0% | 35.0% | 37.0% | 36.0% | 34.0% | 34.0% | 36.0% | 34.0% | ||||
Gross-to-Net Accrued Deductions Liability (Ending Balance)($M)4 | 241 | 270 | 248 | 258 | 206 | 195 | 178 | 160 | 137 | 133 | 131 | 126 | |
Rebates & Chargebacks Accrued Liability($M) | 220 | 251 | 229 | 239 | 188 | 174 | 159 | 141 | 117 | 116 | 114 | 108 | |
Specialty Distributor Fees Accrued Liability($M) | 13.8 | 12 | 11.5 | 11.7 | 11.7 | 11.9 | 11.4 | 11.6 | 11.8 | 9.40 | 8.90 | 10.4 | |
Prompt Pay Discounts Accrued Liability($M) | 6.70 | 6 | 5.70 | 6.30 | 5.60 | 7.30 | 6.30 | 5.10 | 6.30 | 5.60 | 5.50 | 5.30 | |
Allowance for Product Sales Returns($M) | 0.70 | 1 | 1.30 | 1.40 | 1.30 | 1.60 | 1.30 | 2.20 | 2.40 | 1.90 | 2.30 | 1.90 | |
Gross-to-Net Provisions — Current-Period Sales($M)4 | 185 | 167 | 172 | ||||||||||
Gross-to-Net Provisions — Prior-Period Reserve Adjustments($M)4 | -5.70 | -5.40 | -5.90 | ||||||||||
Gross-to-Net Payments & Credits Applied — Current-Period Sales($M)3 | 37.1 | 35.2 | 38.1 | ||||||||||
Gross-to-Net Payments & Credits Applied — Prior-Period Sales($M)4 | 171 | 104 | 138 | ||||||||||
Total Tyvaso Franchise Net Product Sales (DPI + Nebulized)($M)3 | 504 | 453 | 458 | 464 | 478 | 470 | 466 | 416 | 434 | 398 | 373 | 351 | |
Total Tyvaso Franchise — U.S. Net Product Sales($M) | 496 | 436 | 443 | 457 | 470 | 455 | 441 | 409 | 420 | 389 | 361 | 337 | |
Total Tyvaso Franchise — Rest-of-World (ROW) Net Product Sales($M) | 7.60 | 16.3 | 14.6 | 7.10 | 7.90 | 14.3 | 25.2 | 6.70 | 14 | 9.70 | 11.3 | 13.2 | |
Total Tyvaso Franchise — Reported YoY Revenue Change(%) | 5.0% | -4.0% | -2.0% | 12.0% | 10.0% | 18.0% | 25.0% | 19.0% | 33.0% | 25.0% | 56.0% | 45.0% | |
Tyvaso DPI Net Product Sales($M)4 | 379 | 327 | 330 | 339 | 336 | 315 | 303 | 273 | 275 | 258 | 228 | 214 | |
Tyvaso DPI — Reported YoY Revenue Change(%) | 13.0% | 4.0% | 9.0% | 24.0% | 22.0% | 22.0% | 33.0% | 28.0% | 34.0% | 33.0% | 92.0% | 132.0% | |
Tyvaso DPI — Product Cost of Sales($M) | 49.9 | 51.1 | 83.2 | 58.7 | 55.3 | 48.5 | 48.1 | 38.4 | 39.1 | 37.6 | 33.3 | 30.8 | |
Tyvaso DPI — Inventory Write-Downs($M) | 0.40 | 7.90 | 39.2 | 9.60 | 5.10 | 5.80 | |||||||
Tyvaso DPI — Commercial Supply Firm Purchase Commitment Loss($M) | 0.10 | 7.50 | 26.8 | ||||||||||
Nebulized Tyvaso Net Product Sales($M)2 | 125 | 126 | 127 | 126 | 142 | 154 | 164 | 143 | 159 | 140 | 145 | 137 | |
Nebulized Tyvaso — Reported YoY Revenue Change(%) | -12.0% | -18.0% | -22.0% | -12.0% | -11.0% | 10.0% | 13.0% | 4.0% | 32.0% | 12.0% | 21.0% | -9.0% | |
Nebulized Tyvaso — Product Cost of Sales($M) | 6.50 | 8.90 | 8.60 | 6.40 | 6.70 | 5.60 | 8.50 | 7.40 | 9.40 | 8.40 | 8.90 | 9 | |
Orenitram Net Product Sales($M)2 | 145 | 126 | 136 | 121 | 131 | 124 | 121 | 108 | 113 | 107 | 106 | 84.1 | |
Orenitram — Reported YoY Revenue Change(%) | 11.0% | 1.0% | 12.0% | 12.0% | 16.0% | 16.0% | 14.0% | 28.0% | 23.0% | 13.0% | 20.0% | 11.0% | |
Orenitram — Product Cost of Sales($M) | 8.50 | 6.10 | 7.40 | 6.90 | 6.80 | 6.70 | 8.30 | 5.70 | 7.60 | 5.90 | 9.20 | 5.20 | |
Remodulin Net Product Sales (Incl. Remunity Pumps)($M)2 | 122 | 126 | 127 | 128 | 126 | 135 | 138 | 135 | 128 | 147 | 128 | 115 | |
Remodulin — Reported YoY Revenue Change(%) | -3.0% | -6.0% | -8.0% | -5.0% | -2.0% | -9.0% | 8.0% | 17.0% | -2.0% | 16.0% | 5.0% | -6.0% | |
Remodulin — Product Cost of Sales($M) | 16 | 17.4 | 16.1 | 8.10 | 13.1 | 14.3 | 13.8 | 13.4 | 13.3 | 12.8 | 7.90 | 12.2 | |
Unituxin Net Product Sales (High-Risk Neuroblastoma)($M)2 | 52.3 | 65.2 | 53.6 | 62.3 | 47.9 | 58.4 | 58.2 | 67.5 | 61.1 | 51.7 | 58.4 | 54.2 | |
Unituxin — Reported YoY Revenue Change(%) | 9.0% | 12.0% | -8.0% | -8.0% | -22.0% | 13.0% | 0.0% | 25.0% | 19.0% | 17.0% | 19.0% | 48.0% | |
Unituxin — Product Cost of Sales($M) | 5.10 | 2 | 5 | 5.90 | 3.60 | 2.80 | 5.20 | 2.20 | 4.80 | 3.80 | 3.60 | 5 | |
Adcirca Net Product Sales($M)2 | 4.50 | 6.70 | 2.90 | 7.80 | 9.70 | 6.50 | 6 | 4.70 | 7 | 5.70 | 6.40 | 6.80 | |
Adcirca — Reported YoY Revenue Change(%) | -54.0% | 3.0% | -52.0% | 66.0% | 39.0% | 14.0% | -6.0% | -31.0% | -4.0% | -24.0% | -12.0% | -35.0% | |
Adcirca — Product Cost of Sales($M) | 2.10 | 3 | 1 | 3.40 | 4.40 | 2.70 | 2.60 | 1.80 | 3.10 | 2.60 | 2.60 | 2.70 | |
Other Product & Service Revenues($M)2 | 4.90 | 6.80 | 5.30 | 6.60 | 6.90 | 5.50 | 5 | 5.50 | 5.50 | 4.90 | 6.20 | 3.90 | |
United States Consolidated Net Product & Service Revenues($M)1 | 809 | 734 | 744 | 753 | 775 | 760 | 750 | 706 | 717 | 675 | 642 | 586 | |
Consolidated Revenues — Reported YoY Change(%) | 4.0% | -2.0% | -2.0% | 7.0% | 7.0% | 12.0% | 17.0% | 20.0% | 23.0% | 20.0% | 34.0% | 25.0% | |
TETON-PPF Phase 3 Trial Enrollment Progress (Progressive Pulmonary Fibrosis)(%) | 100.0% | 95.0% | 75.0% | ||||||||||
Research & Development Expense (MD&A Disaggregation by Nature)($M)4 | 279 | 146 | 138 | 140 | 128 | 134 | 149 | 134 | 104 | 140 | 104 | 151 | |
External R&D (Clinical Sites, CROs & Pre-Approval CMOs)($M)1 | 77.1 | 71.2 | 57.8 | 62.7 | 63.5 | 62.4 | 57.2 | 63.7 | 51.7 | 49.4 | 52.7 | 50.4 | |
External R&D — Reported YoY Change(%) | 21.0% | 14.0% | 1.0% | -2.0% | 23.0% | 26.0% | 9.0% | 26.0% | 10.0% | 0.0% | 17.0% | 8.0% | |
Internal R&D (Personnel, Pre-Approval Mfg & Lab Facilities)($M)1 | 61 | 54 | 58.3 | 57.3 | 50.8 | 55.9 | 48.3 | 50.3 | 43.9 | 44.5 | 44.9 | 43.2 | |
Internal R&D — Reported YoY Change(%) | 20.0% | -3.0% | 21.0% | 14.0% | 16.0% | 26.0% | 8.0% | 16.0% | 28.0% | 28.0% | 31.0% | 22.0% | |
Other R&D (IPR&D Acquisitions, Upfront Licenses & Milestones)($M) | 130 | 10.2 | 16.7 | 10.6 | 4.80 | 7.60 | 36.6 | 13.1 | 0.50 | 37.1 | 0.10 | 52.1 | |
R&D Share-Based Compensation Expense($M) | 11.1 | 10.9 | 5.40 | 8.90 | 8.40 | 8.10 | 6.90 | 6.70 | 7.40 | 8.60 | 6.40 | 5.70 | |
Selling, General & Administrative Expense (MD&A Disaggregation)($M)3 | 146 | 207 | 184 | 191 | 183 | 213 | 170 | 169 | 219 | 178 | 144 | 132 | |
Cost of Sales Excluding Share-Based Compensation($M)1 | 98 | 98.5 | 132 | 102 | 100 | 86.6 | 91.6 | 74.8 | 81.8 | 75.9 | 71.8 | 70.1 | |
Cost of Sales Share-Based Compensation Expense($M) | 1.10 | 1 | 1 | 1.10 | 0.90 | 1 | 0.90 | 1.10 | 1.30 | 1.90 | 1.10 | 0.90 | |
Inventories by Manufacturing Stage (Total Net)($M)4 | 202 | 194 | 178 | 183 | 177 | 169 | 165 | 158 | 147 | 137 | 120 | 112 | |
Raw Materials Inventory($M) | 35.6 | 32.2 | 34.6 | 30.6 | 31.2 | 32.7 | 34.1 | 28.6 | 23.7 | 22 | 21.6 | 21.7 | |
Work-in-Process (WIP) Inventory($M) | 37.4 | 37.5 | 35.1 | 35.3 | 34.8 | 33.5 | 34.3 | 34.3 | 32.8 | 34.4 | 34.8 | 34.4 | |
Finished Goods Inventory($M) | 129 | 124 | 109 | 117 | 111 | 103 | 97 | 95 | 90.2 | 80.1 | 63.8 | 55.7 | |
Total Inventory Write-Downs Recognized($M) | 11.4 | 19.2 | 44.9 | 11.6 | 6.50 | 9 | |||||||
Gross Property, Plant & Equipment — Commercial & Organ Manufacturing Buildout($M)6 | 2,678 | 2,542 | 2,430 | 2,298 | 2,104 | 1,894 | 1,813 | 1,714 | 1,632 | 1,556 | 1,517 | 1,474 | |
Construction in Progress (Warp-10 & DPF Xenotransplant Facilities)($M) | 767 | 794 | 704 | 593 | 440 | 329 | 277 | 218 | 176 | 110 | 96.8 | 259 | |
Buildings, Cleanrooms & Leasehold Improvements (Gross)($M) | 1,054 | 955 | 950 | 945 | 917 | 889 | 869 | 864 | 852 | 852 | 837 | 685 | |
Laboratory, Bioprocessing & Manufacturing Equipment (Gross)($M) | 537 | 517 | 510 | 494 | 484 | 483 | 475 | 450 | 441 | 441 | 431 | 381 | |
Owned Land & Campus Acreage Carrying Value($M) | 321 | 276 | 267 | 267 | 264 | 193 | 193 | 182 | 163 | 153 | 152 | 148 | |
Advance Payments on Manufacturing Equipment($M) | 3.50 | 0.70 | 5.70 | -5.10 | 5.70 | 0.60 | 9.20 | 6 | 17.8 | 0.40 | 4.30 | 8.70 | |
Accumulated Depreciation($M) | 636 | 612 | 589 | 568 | 549 | 531 | 511 | 491 | 476 | 461 | 443 | 428 | |
Share-Based Compensation Expense by Award Vehicle($M)4 | 41 | 43.4 | 33.9 | 39 | 39.1 | 37.8 | 31.8 | 27 | 41.7 | 49.7 | 25.6 | 16.6 | |
Restricted Stock Units (RSUs) Expense($M) | 29.1 | 29.7 | 21.5 | 26.6 | 27.1 | 26 | 23.4 | 17.8 | 27.2 | 19.2 | 15.5 | 14.1 | |
Stock Options Expense($M) | 11 | 12.8 | 11.5 | 11.4 | 11.3 | 11.1 | 8.50 | 8 | 8 | 8.10 | 5.70 | 2.90 | |
Employee Stock Purchase Plan (ESPP) Expense($M) | 0.90 | 0.90 | 0.90 | 1 | 0.70 | 0.70 | 0.70 | 0.60 | 0.60 | 0.50 | 0.50 | 0.50 | |
Share Tracking Awards Plan (STAP) Cash-Settled Phantom Award Expense($M) | 0 | 0 | 0 | 0 | 0 | 0 | -0.80 | 0.60 | 5.90 | 21.9 | 3.90 | -0.90 | |
Stock Options Outstanding (Period-End)5 | 2,887,103 | 3,535,049 | 4,430,774 | 4,636,330 | 5,378,590 | 5,655,511 | 5,794,037 | 5,571,545 | 5,784,521 | 6,024,234 | 6,420,863 | 6,213,853 | |
Stock Options Exercisable | 1,708,761 | 2,348,347 | 3,243,872 | 3,312,354 | 4,054,614 | 4,339,265 | 4,476,271 | 4,592,793 | 4,805,769 | 5,029,432 | 5,427,581 | 5,741,239 | |
Stock Options Weighted-Average Exercise Price($) | 226 | 207 | 193 | 166 | 162 | 160 | 159 | 149 | 148 | 146 | 145 | 137 | |
Stock Options Outstanding — Aggregate Intrinsic Value($M) | 913 | 1,185 | 1,770 | 1,489 | 1,386 | 731 | 867 | 1,138 | 1,219 | 1,038 | 546 | 518 | |
Unrecognized Stock Option Compensation Cost($M) | 68.7 | 84.2 | 97 | 53.3 | 64.1 | 73.3 | 84.4 | 53.7 | 62 | 68 | 75.9 | 25.4 | |
Cash Proceeds from Employee Stock Option Exercises($M) | 87.4 | 126 | 68.3 | 99 | 40.2 | 18.1 | 16.6 | 25.7 | 32.5 | 52.1 | 42.2 | 7.30 | |
Unvested Restricted Stock Units (RSUs) Outstanding2 | 1,419,103 | 1,419,246 | 1,421,031 | 1,416,871 | 1,421,173 | 1,430,154 | 1,437,477 | 1,219,654 | 1,232,376 | 1,208,771 | 1,212,383 | 964,759 | |
Unvested RSUs — Weighted-Average Grant-Date Fair Value($) | 315 | 313 | 312 | 253 | 253 | 252 | 252 | 225 | 225 | 221 | 221 | 210 | |
Unrecognized RSU Compensation Cost($M) | 210 | 242 | 273 | 165 | 187 | 209 | 236 | 157 | 185 | 185 | 205 | 133 | |
Treasury Stock Held in Treasury (Shares)(M)2 | 36.3 | 35.4 | 35.0 | 32.8 | 32.8 | 30.2 | 30.2 | 30.2 | 30.2 | 30.1 | 29.9 | 26.6 | |
Treasury Stock Carrying Cost($M) | 6,139 | 5,645 | 5,442 | 4,260 | 4,262 | 3,475 | 3,475 | 3,475 | 3,475 | 3,444 | 3,386 | 2,579 | |
Cash Paid for Common Stock Repurchases (ASR & Open Market)($M) | 500 | 0 | 1,500 | 0 | 1,000 | 0 | 0 | 0 | 0 | 0 | 1,000 | 0 | |
Available-for-Sale Marketable Debt Securities (Fair Value)($M)4 | 2,251 | 1,922 | 2,126 | 3,050 | 3,019 | 3,785 | 3,276 | 3,043 | 3,031 | 2,953 | 2,969 | 3,757 | |
MannKind Corporation (MNKD) — Total Revenue Earned from United Therapeutics($M)4 | 56.3 | 66.9 | 55.8 | 59.9 | 59.3 | 53.5 | 58.8 | 52.1 | 50.3 | 51.6 | 47.5 | 38.2 | |
MannKind Corporation (MNKD) — Tyvaso DPI Commercial Supply Manufacturing Revenue($M) | 16.5 | 29.6 | 22 | 25.4 | 26 | 22.2 | 28.8 | 22.6 | 23.2 | 26 | 24.5 | 17.1 | |
MannKind Corporation (MNKD) — Tyvaso DPI 10% Royalty Revenue($M) | 37.5 | 32.4 | 32.7 | 33.6 | 33.3 | 31.2 | 30 | 27 | 27.1 | 25.6 | 22.7 | 21 | |
MannKind Corporation (MNKD) — Non-Cash 1% Tyvaso DPI Royalty Sold to Sagard($M) | 3.70 | 3.20 | 3.30 | 3.40 | 3.30 | 3.10 | 3 | 2.70 | 2.70 | ||||
MannKind Corporation (MNKD) — Deferred Revenue on UTHR Supply Agreement($M)2 | 43.4 | 44.9 | 50.4 | 51.3 | 57.2 | 55.4 | 58 | 62.4 | 70.5 | 72.3 | 74 | 77.5 | |
Consolidated Total Revenues($M)2 | 833 | 783 | 782 | 790 | 800 | 799 | 794 | 736 | 749 | 715 | 678 | 615 | |
Cost of Sales($M) | 99.1 | 99.5 | 133 | 103 | 101 | 87.6 | 92.5 | 75.9 | 83.1 | 77.8 | 72.9 | 71 | |
Gross Profit($M) | 733 | 684 | 648 | 687 | 699 | 711 | 702 | 660 | 666 | 637 | 605 | 544 | |
Operating Income($M)2 | 308 | 331 | 326 | 357 | 389 | 365 | 383 | 358 | 343 | 320 | 356 | 260 | |
Research & Development Expense($M) | 279 | 146 | 138 | 140 | 128 | 134 | 149 | 134 | 104 | 140 | 104 | 151 | |
Selling, General & Administrative Expense($M) | 146 | 207 | 184 | 191 | 183 | 213 | 170 | 169 | 219 | 178 | 144 | 132 | |
Net Income($M)2 | 259 | 333 | 275 | 364 | 339 | 310 | 322 | 301 | 309 | 278 | 307 | 217 | |
Diluted Earnings per Share($) | 5.71 | 7.27 | 5.82 | 7.16 | 6.41 | 6.63 | 6.39 | 5.85 | 6.17 | ||||
Weighted-Average Diluted Shares(M) | 45.3 | 45.8 | 47.2 | 47.3 | 48.3 | 48.6 | 48.4 | 47.5 | 49.7 | ||||
Cash, Cash Equivalents & Short-Term Marketable Investments3 | |||||||||||||
Cash & Cash Equivalents($M) | 1,189 | 1,803 | 1,280 | 1,557 | 1,340 | 1,593 | 1,900 | 1,697 | 1,554 | 1,356 | 1,252 | 1,208 | |
Short-Term Marketable Investments($M) | 879 | 859 | 874 | 1,363 | 1,428 | 1,456 | 1,421 | 1,570 | 1,773 | 1,616 | 1,456 | 1,786 | |
Long-Term Marketable Investments($M) | 1,468 | 1,141 | 1,317 | 1,777 | 1,567 | 1,918 | 1,711 | 1,475 | 1,279 | 1,330 | 1,492 | 1,910 | |
Total Assets($M)5 | 7,034 | 7,220 | 6,714 | 7,880 | 7,351 | 7,908 | 7,744 | 7,364 | 7,123 | 6,723 | 6,495 | 7,167 | |
Accounts Receivable, Net($M) | 349 | 310 | 312 | 350 | 298 | 379 | 322 | 279 | 342 | 291 | 307 | 279 | |
Inventories, Net($M) | 202 | 194 | 178 | 183 | 177 | 169 | 165 | 158 | 147 | 137 | 120 | 112 | |
Property, Plant & Equipment, Net($M) | 2,042 | 1,930 | 1,841 | 1,730 | 1,556 | 1,362 | 1,303 | 1,222 | 1,157 | 1,095 | 1,074 | 1,045 | |
Total Liabilities($M) | 758 | 820 | 813 | 784 | 761 | 734 | 937 | 920 | 1,022 | 1,026 | 1,157 | 1,182 | |
Stockholders' Equity($M) | 6,276 | 6,400 | 5,901 | 7,096 | 6,590 | 7,174 | 6,807 | 6,444 | 6,101 | 5,697 | 5,338 | 5,985 | |
Operating Cash Flow($M)4 | 307 | 314 | 463 | 346 | 562 | 192 | 461 | 341 | 377 | 232 | 377 | 151 | |
Capital Expenditures($M) | 181 | 108 | 101 | 173 | 211 | 62.2 | 74.9 | 86.7 | 76.5 | 45.1 | 38.2 | 78.7 | |
Depreciation & Amortization($M) | 26.4 | 24.2 | 22.6 | 22.8 | 21.9 | 21.1 | 19.8 | 19.7 | 19.1 | 18.7 | 15 | 13.7 | |
Stock-Based Compensation (Cash Flow)($M) | 41 | 43.4 | 33.9 | 39 | 39.1 | 37.8 | 31.8 | 27 | 41.7 | 49.7 | 25.6 | 16.6 | |
Common Stock Repurchases (Cash Outflow)($M) | 500 | -0 | 1,500 | -0 | 1,000 | -0 | -0 | -0 | -0 | -0 | 1,000 | -0 | |
2 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar: United Therapeutics Corporation (a Delaware Public Benefit Corporation) operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026).
- Core commercial & channel KPIs (Key #1 and Key #2) track U.S. specialty distributor concentration (top two distributors accounted for 50% and 40% — 90% combined — of Q3 2026 total revenues), the complete Gross-to-Net (GTN) rebate, chargeback, discount, return, and fee reserve rollforward ($241.2M accrued liability at September 30, 2026; $638.2M current-year sales provisions in FY2025 and $184.5M in Q3 2026), and complete U.S. vs. Rest-of-World net product sales, company-reported YoY percentage growth, and product-level gross profit and cost of sales across Tyvaso DPI ($378.5M, +13% YoY in Q3 2026), Nebulized Tyvaso ($125.3M, -12% YoY), Orenitram ($145.0M, +11% YoY), Remodulin ($122.0M, -3% YoY), Unituxin ($52.3M, +9% YoY), Adcirca ($4.5M), and Other ($4.9M).
- Supply-chain & subsidiary cross-checks: Exclusive Tyvaso DPI manufacturer MannKind Corporation (NASDAQ: MNKD) independently reports quarterly commercial supply manufacturing revenue ($29.7M in Q3 2026) and its 10% contractual royalty on Tyvaso DPI net sales ($37.5M in Q3 2026, matching 9.90% of UTHR's $378.5M reported Tyvaso DPI net sales). Wholly owned UK subsidiary United Therapeutics Europe, Ltd. (#03938816) is covered via OCR-verified UK Companies House statutory balance sheets and employee counts (FY2018–FY2025). Monthly BLS pharmaceutical and biological Producer Price Indices and medical Consumer Price Indices update through October 2026.
- Accounting & calculation discipline: United Therapeutics files consolidated U.S. GAAP financial statements only (no parent-only standalone financial statements exist). All displayed numbers are strictly as published except standalone Q4 / quarterly splits of cumulative year-to-date figures where explicitly labeled with the period-splitting formula.
Không hiện vì thiếu các kỳ gần đây (12)
- Commercial Channel Concentration & Gross-to-Net (GTN) Reserves (Key #1) › Top Specialty Distributor #3 — Share of Total Revenues (≥10% Threshold)
- External Supply-Chain Partner (MannKind) & U.S. Pharmaceutical Industry Benchmarks › U.S. Retail Sales — Pharmacies & Drug Stores (Census MRTSSM44611USS)
- External Supply-Chain Partner (MannKind) & U.S. Pharmaceutical Industry Benchmarks › CMS Medicare Part D — Tyvaso DPI Beneficiaries
- External Supply-Chain Partner (MannKind) & U.S. Pharmaceutical Industry Benchmarks › CMS Medicare Part D — Orenitram ER Beneficiaries
- External Supply-Chain Partner (MannKind) & U.S. Pharmaceutical Industry Benchmarks › CMS Medicare Part D — Remodulin Beneficiaries
- Financial Context (GAAP, from DB) › Total Assets › Goodwill
- Commercial Patients Currently Treated Across Therapies — Disclosed only as a lower bound ('Over 15,500 patients') for FY2024 in the 2025 Proxy Statement, breaking annual continuity between exact/approximate point disclosures in FY2021 (~10,000), FY2022 (12,592), FY2023 (14,517), and FY2025 (~17,000).
- Centralized Ex-Vivo Lung Perfusion (EVLP) Lung Transplant Recipients — Cumulative transplant figures are disclosed only as lower bounds in FY2024 ('Over 500 patients') and FY2025 ('Over 730 patients'), while single-year volume (179 lung transplant recipients) is disclosed only for FY2025.
- TETON-1, TETON-2 & ADVANCE OUTCOMES Enrolled Patient Counts — Completed static trial cohort totals (598, 597, and 728 enrolled patients, respectively) rather than ongoing quarterly time-series metrics through Q3 2026.
- Workforce Gender & Racial/Ethnic Representation (%) — Disclosed in FY2020–FY2023 Form 10-K filings (50%–52% women; 35%–36% racial/ethnic minority) but omitted from FY2024 and FY2025 Form 10-K filings.
- United Therapeutics Europe, Ltd. Standalone Revenue & Operating Profit — Omitted from public UK Companies House filings under Section 444(5B) of the UK Companies Act 2006 small-companies filleted accounts exemption.
- Scope 1, Scope 2 & Scope 3 Greenhouse Gas Emissions and Campus Energy/Water Volumes — Not published as a multi-year quantitative table across FY2024–FY2025 in the Corporate Responsibility & PBC Reports.
Dữ liệu cập nhật 2026-11-15.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Commercial Channel Concentration & Gross-to-Net (GTN) Reserves (Key #1)
- Top Specialty Distributor #1 — Share of Total Revenues (%)21 kỳ
- Top Specialty Distributor #2 — Share of Total Revenues (%)21 kỳ
- Gross-to-Net Accrued Deductions Liability (Ending Balance) ($M)25 kỳ
- Gross-to-Net Provisions — Current-Period Sales ($M)8 kỳ
- Gross-to-Net Provisions — Prior-Period Reserve Adjustments ($M)8 kỳ
- Gross-to-Net Payments & Credits Applied — Current-Period Sales ($M)8 kỳ
- Gross-to-Net Payments & Credits Applied — Prior-Period Sales ($M)8 kỳ
Commercial Therapies — U.S. vs. Rest-of-World, YoY Growth & Product Economics (Key #2)
- Total Tyvaso Franchise Net Product Sales (DPI + Nebulized) ($M)27 kỳ
- Tyvaso DPI Net Product Sales ($M)17 kỳ
- Nebulized Tyvaso Net Product Sales ($M)27 kỳ
- Orenitram Net Product Sales ($M)27 kỳ
- Remodulin Net Product Sales (Incl. Remunity Pumps) ($M)27 kỳ
- Unituxin Net Product Sales (High-Risk Neuroblastoma) ($M)27 kỳ
- Adcirca Net Product Sales ($M)27 kỳ
- Other Product & Service Revenues ($M)23 kỳ
- United States Consolidated Net Product & Service Revenues ($M)27 kỳ
R&D Execution, Clinical Enrollment, Inventory Stages & Organ/DPF Infrastructure
- TETON-PPF Phase 3 Trial Enrollment Progress (Progressive Pulmonary Fibrosis) (%)3 kỳ
- Research & Development Expense (MD&A Disaggregation by Nature) ($M)21 kỳ
- Selling, General & Administrative Expense (MD&A Disaggregation) ($M)27 kỳ
- Cost of Sales Excluding Share-Based Compensation ($M)20 kỳ
- Inventories by Manufacturing Stage (Total Net) ($M)25 kỳ
- Gross Property, Plant & Equipment — Commercial & Organ Manufacturing Buildout ($M)25 kỳ
- Silver Spring, MD Co-HQ, API Synthesis & EVLP Lung Center Area (nghìn ft²)3 kỳ
- Long-Lived Assets (PP&E & Lease ROU Assets) — Worldwide ($M)6 kỳ
Public Benefit Corporation (PBC), Workforce Safety, Equity Overhang & Capital Return
- Worldwide Employees (Unitherians)7 kỳ
- OSHA Recordable Injury & Illness Rate (per 100 Full-Time Workers) (×)3 kỳ
- Share-Based Compensation Expense by Award Vehicle ($M)27 kỳ
- Stock Options Outstanding (Period-End)25 kỳ
- Unvested Restricted Stock Units (RSUs) Outstanding25 kỳ
- Treasury Stock Held in Treasury (Shares) (M)25 kỳ
- Available-for-Sale Marketable Debt Securities (Fair Value) ($M)20 kỳ
United Therapeutics Europe, Ltd. (UK Subsidiary #03938816)
External Supply-Chain Partner (MannKind) & U.S. Pharmaceutical Industry Benchmarks
- MannKind Corporation (MNKD) — Total Revenue Earned from United Therapeutics ($M)19 kỳ
- U.S. Producer Price Index — Pharmaceutical Preparation Manufacturing (BLS PCU325412325412)94 kỳ
- U.S. Producer Price Index — Biological Product Manufacturing (BLS PCU325414325414)94 kỳ
- U.S. Consumer Price Index — Medical Care Commodities & Rx Drugs (BLS CUSR0000SAM1)93 kỳ
- U.S. Consumer Price Index — Medical Care Overall (BLS CPIMEDSL)93 kỳ
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của United Therapeutics
- United Therapeutics 10-Q (period ended 2026-09-30, filed 2026-11-04) ↗
- United Therapeutics 10-K (period ended 2025-12-31, filed 2026-02-25) ↗
- United Therapeutics Q3 2026 Investor Presentation ↗
- United Therapeutics FY2025 Corporate Responsibility & Public Benefit Corporation Report ↗
- United Therapeutics Europe, Ltd. — UK Companies House Audited Filleted Accounts (FY2025, #03938816) ↗
- MannKind Corp. (MNKD) 10-Q (period ended 2026-09-30, filed 2026-11-05) ↗
- MannKind Corp. (MNKD) 10-K (period ended 2025-12-31, filed 2026-02-26) ↗
- BLS Producer Price Index — Pharmaceutical Preparation Manufacturing (PCU325412325412) via FRED ↗
- BLS Producer Price Index — Biological Product (Excl. Diagnostic) Manufacturing (PCU325414325414) via FRED ↗
- BLS Consumer Price Index — U.S. Medical Care Commodities, Rx & OTC Drugs (CUSR0000SAM1) via FRED ↗
- BLS Consumer Price Index — U.S. Medical Care Services & Commodities (CPIMEDSL) via FRED ↗
See a number that looks wrong?